Paradigm Shifts in Hodgkin Lymphoma Treatment: From Frontline Therapies to Relapsed Disease
C Burton, P Allen, AF Herrera - American Society of Clinical Oncology …, 2024 - ascopubs.org
Combination chemotherapy with or without radiation has served as the primary therapeutic
option for classic Hodgkin lymphoma (cHL), leading to durable remission in a majority of …
option for classic Hodgkin lymphoma (cHL), leading to durable remission in a majority of …
When should we use it? The role of brentuximab vedotin in 2024
JG Schroers-Martin, R Advani - Hematology, 2024 - ashpublications.org
The CD30-directed antibody-drug conjugate brentuximab vedotin (BV) was FDA approved
in 2011 for the treatment of relapsed classic Hodgkin lymphoma (cHL), in 2015 for …
in 2011 for the treatment of relapsed classic Hodgkin lymphoma (cHL), in 2015 for …
Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30+ lymphoma: a phase 1 study
NS Grover, G Hucks, ML Riches, A Ivanova… - The Lancet …, 2024 - thelancet.com
Background Chimeric antigen receptor (CAR) T cells targeting CD30 are safe and have
promising activity when preceded by lymphodepleting chemotherapy. We aimed to …
promising activity when preceded by lymphodepleting chemotherapy. We aimed to …
[PDF][PDF] A Comprehensive Review on Unravelling the Complexity of Blood Cancer
S Saha, S Ghosh, S Ghosh, S Nandi - blood - academia.edu
Blood cancer also referred to as haematological carcinoma, is a large category of
malignancies that affects the bone marrow, lymphatic as well as blood systems. This …
malignancies that affects the bone marrow, lymphatic as well as blood systems. This …